Log in
NASDAQ:VRTX

Vertex Pharmaceuticals News Headlines

$211.58
+1.50 (+0.71 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$209.07
Now: $211.58
$213.51
50-Day Range
$210.08
MA: $258.40
$281.89
52-Week Range
$189.35
Now: $211.58
$306.08
Volume1.72 million shs
Average Volume2.28 million shs
Market Capitalization$55.11 billion
P/E Ratio26.71
Dividend YieldN/A
Beta0.79

Headlines

Vertex Pharmaceuticals (NASDAQ VRTX) News Headlines Today

Source:
DateHeadline
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $249.00 by Analysts at Morgan StanleyVertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $249.00 by Analysts at Morgan Stanley
marketbeat.com - October 19 at 9:13 AM
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Sell by BidaskClubVertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Sell by BidaskClub
marketbeat.com - September 25 at 6:10 AM
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Lowered by BidaskClubVertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Lowered by BidaskClub
marketbeat.com - August 26 at 1:26 AM
Vertex Pharmaceuticals (NASDAQ: VRTX) Continues To Lead From The Front (VRTX)Vertex Pharmaceuticals (NASDAQ: VRTX) Continues To Lead From The Front (VRTX)
marketbeat.com - August 3 at 2:09 PM
BioMarin Pharmaceutical (NASDAQ: BMRN) Looks Ready to Fulfill Potential (VRTX)BioMarin Pharmaceutical (NASDAQ: BMRN) Looks Ready to Fulfill Potential (VRTX)
marketbeat.com - August 3 at 2:08 PM
Biotech Stocks - Best Biotech Stocks to Buy (VRTX)Biotech Stocks - Best Biotech Stocks to Buy (VRTX)
marketbeat.com - August 3 at 2:08 PM
Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to Sell at BidaskClubVertex Pharmaceuticals (NASDAQ:VRTX) Lowered to Sell at BidaskClub
marketbeat.com - August 1 at 1:19 AM
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?
finance.yahoo.com - October 23 at 12:57 PM
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other UpdatesBiotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
msn.com - October 22 at 7:44 PM
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Expected to Post Earnings of $2.35 Per ShareVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Expected to Post Earnings of $2.35 Per Share
americanbankingnews.com - October 20 at 9:08 PM
Vertex Pharmaceuticals (VRTX) Enters Oversold TerritoryVertex Pharmaceuticals (VRTX) Enters Oversold Territory
nasdaq.com - October 20 at 12:58 PM
Morgan Stanley Cuts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $249.00Morgan Stanley Cuts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $249.00
americanbankingnews.com - October 19 at 10:37 AM
Vertex: Looks Cheap, But I Have A Few ConcernsVertex: Looks Cheap, But I Have A Few Concerns
seekingalpha.com - October 18 at 5:41 PM
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer ConferenceThe Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
benzinga.com - October 18 at 1:14 PM
P/E Ratio Insights for Vertex PharmaceuticalsP/E Ratio Insights for Vertex Pharmaceuticals
benzinga.com - October 17 at 6:20 AM
Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20%Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20%
seekingalpha.com - October 16 at 12:44 PM
Vertex (VRTX) Drops 20% After Failed Drug TrialVertex (VRTX) Drops 20% After Failed Drug Trial
investopedia.com - October 16 at 12:44 PM
Vertex Pulls Nasdaq Down, but Wall Street Loves ZoomVertex Pulls Nasdaq Down, but Wall Street Loves Zoom
fool.com - October 15 at 4:32 PM
Vertex (VRTX) is an Incredible Growth Stock: 3 Reasons WhyVertex (VRTX) is an Incredible Growth Stock: 3 Reasons Why
nasdaq.com - October 15 at 4:32 PM
Why Arrowhead Pharmaceuticals Is Trading Higher TodayWhy Arrowhead Pharmaceuticals Is Trading Higher Today
feeds.benzinga.com - October 15 at 3:56 PM
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $305.00Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $305.00
americanbankingnews.com - October 15 at 12:10 PM
The Dow Is Slumping, Fastly Is Tumbling, and Vertex Is TankingThe Dow Is Slumping, Fastly Is Tumbling, and Vertex Is Tanking
barrons.com - October 15 at 11:31 AM
Vertex Pharmaceuticals, Infosys leads premarket losers packVertex Pharmaceuticals, Infosys leads premarket losers' pack
seekingalpha.com - October 15 at 11:31 AM
Vertex Stock Sinks After a Surprise Halt to a Promising Protein-Deficiency Drug TrialVertex Stock Sinks After a Surprise Halt to a Promising Protein-Deficiency Drug Trial
barrons.com - October 15 at 11:31 AM
Analysts say Vertexs stock is under pressure after drug development failureAnalysts say Vertex's stock is under pressure after drug development failure
msn.com - October 15 at 11:31 AM
Vertex to End Phase II Study on AAT Deficiency CandidateVertex to End Phase II Study on AAT Deficiency Candidate
nasdaq.com - October 15 at 11:31 AM
Why Vertex Pharmaceuticals Stock Is Slumping TodayWhy Vertex Pharmaceuticals Stock Is Slumping Today
fool.com - October 15 at 11:31 AM
Vertex shuts down trial of liver drug, spurring a selloffVertex shuts down trial of liver drug, spurring a selloff
bizjournals.com - October 15 at 6:31 AM
Vertex Pharma -7.9% as it drop VX-814 study, developmentVertex Pharma -7.9% as it drop VX-814 study, development
seekingalpha.com - October 14 at 5:37 PM
Vertex Pharmaceuticals (NASDAQ:VRTX) PT Lowered to $281.00Vertex Pharmaceuticals (NASDAQ:VRTX) PT Lowered to $281.00
americanbankingnews.com - October 13 at 12:01 PM
VRTX Oct 2020 277.500 callVRTX Oct 2020 277.500 call
uk.finance.yahoo.com - October 8 at 9:01 AM
Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Sells 10,516 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Sells 10,516 Shares of Stock
americanbankingnews.com - October 7 at 6:55 PM
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Rating of "Buy" by AnalystsVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - October 4 at 5:40 AM
Where Will Vertex Pharmaceuticals Be in 5 Years?Where Will Vertex Pharmaceuticals Be in 5 Years?
fool.com - October 3 at 9:22 AM
Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in InfantsVertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants
finance.yahoo.com - September 28 at 6:27 PM
Vertexs Kalydeco Gets FDA Nod for Cystic Fibrosis in InfantsVertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants
nasdaq.com - September 28 at 1:26 PM
Vertex gets FDA nod to Kalydeco for cystic fibrosis in 4-6 month infantsVertex gets FDA nod to Kalydeco for cystic fibrosis in 4-6 month infants
seekingalpha.com - September 26 at 1:14 PM
Vertex gets FDA nod to Kalydeco for cystic fibrosis in 4 to 6-month infantsVertex gets FDA nod to Kalydeco for cystic fibrosis in 4 to 6-month infants
seekingalpha.com - September 25 at 12:54 PM
FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of AgeFDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
finance.yahoo.com - September 25 at 12:54 PM
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR ModulatorsVertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators
finance.yahoo.com - September 24 at 7:50 AM
Vertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should KnowVertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should Know
finance.yahoo.com - September 21 at 6:38 PM
European advisory group backs expanded use of Vertexs KalydecoEuropean advisory group backs expanded use of Vertex's Kalydeco
seekingalpha.com - September 18 at 8:47 AM
Moderna Stock Rises 3% On Vertex DealModerna Stock Rises 3% On Vertex Deal
finance.yahoo.com - September 17 at 10:46 PM
Moderna Shares the Latest on its Coronavirus Vaccine Trial and Other Research AdvancesModerna Shares the Latest on its Coronavirus Vaccine Trial and Other Research Advances
finance.yahoo.com - September 17 at 5:45 PM
Stock Market Crash 2.0: Here Are 3 Stocks You'll Absolutely, Positively Want to BuyStock Market Crash 2.0: Here Are 3 Stocks You'll Absolutely, Positively Want to Buy
finance.yahoo.com - September 17 at 7:43 AM
Moderna expands cystic fibrosis partnership with Vertex PharmaModerna expands cystic fibrosis partnership with Vertex Pharma
seekingalpha.com - September 16 at 8:56 PM
Vertex Eyes Label Expansion of Triple Combo CF Drug in EuropeVertex Eyes Label Expansion of Triple Combo CF Drug in Europe
finance.yahoo.com - September 15 at 1:25 PM
Vertex Announces EMA Type II Variation Marketing Authorization Application Validation For KAFTRIOVertex Announces EMA Type II Variation Marketing Authorization Application Validation For KAFTRIO
nasdaq.com - September 14 at 7:22 AM
EC validates Vertexs marketing application for expanded use of Kaftiro + IvacaftorEC validates Vertex's marketing application for expanded use of Kaftiro + Ivacaftor
seekingalpha.com - September 14 at 7:22 AM
Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del MutationVertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation
finance.yahoo.com - September 14 at 7:22 AM
Vertex Pharmaceuticals Reports Positive Phase 3 Results in Children for Blockbuster CF DrugVertex Pharmaceuticals Reports Positive Phase 3 Results in Children for Blockbuster CF Drug
fool.com - September 10 at 3:58 PM
Vertex to file U.S. application for expanded use of Trikafta next quarterVertex to file U.S. application for expanded use of Trikafta next quarter
seekingalpha.com - September 10 at 2:27 PM
Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory ApprovalsVertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals
finance.yahoo.com - September 10 at 2:27 PM
Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term BuyRelay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy
seekingalpha.com - September 7 at 4:02 AM
Next Coronavirus Market Crash: Where to Invest $1,000Next Coronavirus Market Crash: Where to Invest $1,000
finance.yahoo.com - September 4 at 2:21 PM
Vertex Pharmaceuticals reports 7.1% stake in Kymera TherapeuticsVertex Pharmaceuticals reports 7.1% stake in Kymera Therapeutics
seekingalpha.com - September 3 at 6:02 PM
IBD 50 Stocks To Watch: This Drugmaker With Perfect Rating Builds BaseIBD 50 Stocks To Watch: This Drugmaker With Perfect Rating Builds Base
finance.yahoo.com - September 3 at 6:01 PM
This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.